Introduction
Multiple myeloma is characterised by neoplastic proliferation of monoclonal plasma cells. These neoplastic plasma cells are thought to be derived from a post-germinal centre Bcell, which migrates to the bone marrow, adheres to the marrow stroma, and triggers subsequent bone resorption and a paracrine cytokine loop that involves interleukin (IL)-6.
1,2
The natural course of the disease may progress through monoclonal gammopathy of undetermined significance (MGUS), smouldering myeloma, intramedullary myeloma and eventually extramedullary myeloma. MGUS is a precursor of myeloma, and the median interval from discovery of the M-protein to the development of myeloma might be up to 10 years. 3, 4 The binding of cytokines to their receptors results in the dimerization of receptor complexes and activation of the Janus family of protein tyrosine kinases (JAKs), [5] [6] [7] followed by phosphorylation of the cytoplasmic signal transducers and activators of transcription (STATs). Upon phosphorylation, STATs form homo-or hetero-dimers, migrate to the nucleus and activate gene transcription. In myeloma, binding of the IL-6 to its membrane receptor induces dimerization of receptor subunit gp130, and results in activation of Jak by cross-phosphorylation. 8 This Jak/STAT pathway is subject to negative regulation by three family of proteins, the protein inhibitors of activated STATs (PIAS), the suppressors of cytokine signalling (SOCS), and the SH2-containing phosphatases (SHP). 6, 7, 9 The SOCS family comprises at least eight members characterized by the presence of a central src homology (SH2) domain and a conserved carboxy terminal "SOCS box". 6,7 SOCS members are cytokine-inducible negative regulators of the cytokine signalling. An important member is SOCS1. The SOCS1 gene can be induced by a multitude of cytokines including IL-1, IL-3, IL-6, erythropoietin, granulocyte-macrophage colony stimulating factor, andinterferon. [10] [11] [12] Human SOCS1 is a single-exon gene encoding 211 amino acids, and lies
For personal use only. on April 13, 2017 . by guest www.bloodjournal.org From within a CpG island spanning 2.5 kb. The expression of SOCS1 impairs cellular response to IL-6 through direct interaction with Jak proteins. 13 SHP-1 (also known as HCP, SHPTP1 and PTP1C), a member of the SHP family of proteins, is a 68-kd, cytoplasmic protein tyrosine phosphatase (PTP). 14 The human SHP-1 gene consists of 17 exons and spans approximately 17 kb of DNA. It contains two tandem Src homology (SH2) domains, a catalytic domain, and a C-terminal tail of about 100 amino acid residues. 14 In contrast to the ubiquitous expression of the structurally related SHP2, SHP1 is primarily expressed in hematopoietic cells, and considered a putative tumor suppressor gene in lymphoma and leukemias, as it antagonises the growth-promoting and oncogenic potentials of protein tyrosine kinase.
14 DNA methylation, catalysed by DNA methyltransferase, involves the addition of a methyl group to the carbon 5 position of the cytosine ring in the CpG dinucleotide, leading to a conversion to methylcytosine. [15] [16] [17] In many cancers, the CpG islands of selected genes are aberrantly methylated (hypermethylated), resulting in transcriptional repression of these genes. 18 This may serve as an alternative epigenetic mechanism of gene inactivation. 19, 20 Dysregulation of the IL-6/Jak/STAT pathway has been shown to be involved in hematologic cancers. For instance, activation of STAT3 is frequent in primary human myeloma or myeloma cell line, 13 and blocking of either IL-6 receptor, Jak or STAT3 inhibits the expression of Bcl-X L , and promotes apoptosis in myeloma cells. Moreover, a TEL-JAK2 fusion protein is expressed as a consequence of t(9;12)(p24;p13) in some T-ALL. 21 Recently, hypermethylation of SOCS1 has been separately reported in hepatoma. 22, 23 In this study, we investigated the potential involvement of SOCS1 and SHP1 promoter hypermethylation in the pathogenesis of myeloma.
For personal use only. on April 13, 2017 . by guest www.bloodjournal.org From DNA sequencing. The identity of the methylated and unmethylated sequences was confirmed by automated DNA sequencing. PCR products were gel purified, sequenced bi-directionally, and analysed on an automated DNA sequence analyser (3700 ABI Prism, PE Biosystem). gene. 32 The results showed that in normal DNA, significant CpG methylation occurred beyond exon 3 but not in intron 2, while for leukemic samples variable methylation of CpG dinucleotides occurred both 5' and 3' to exon 3. Therefore, a boundary sequence within the HIC1 CpG island existed that marked the junction between methylated and unmethylated DNA in normal hematopoietic cells. 32 Therefore, the presence of a methylation boundary underscores the importance of selecting MSP primers from the 5'UTR region. Conversely, MSP primers selected inside the coding regions might overestimate the frequency of methylation.
Materials and methods
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SOCS1 binds to the conserved regulatory tyrosine in the activation loop of the Jak2 kinase (JH1) domain through its SH2 domain, and inhibits Jak kinase activity. 33, 34 As a negative regulator of the signalling pathway for IL-6, SOCS1 is an attractive target of dysregulation in myeloma. However, we showed that SOCS1, being a potential tumour suppressor in myeloma, 35 was infrequently inactivated by methylation. This contrasted with a previous study using MSP3' primers from the coding DNA region, 36 which showed SOCS1 methylation in 63% of myeloma patients. This disparity might be partly explained by overestimation of the frequency of SOCS1 methylation using MSP primers in the coding region.
Moreover, a less important role of SOCS1 in the pathogenesis of myeloma has also been demonstrated in SOCS1-deficient mice, which died of a myeloproliferative disease instead of plasma cell dyscrasia. 7, 10 On the other hand, SHP1, a protein tyrosine phosphatase important in the negative regulation of Jak/STAT signalling, has been shown to be frequently silenced by methylation in leukemias and lymphomas. 37, 38 In this study, we showed frequent SHP1 methylation in our myeloma patients, suggesting that it might be involved in the pathogenesis through dysregulation of the Jak/STAT pathway. was constitutively activated in U266, which expressed high levels of bcl-X L and was resistant to Fas-mediated apoptosis. 13 Our study further showed that SHP1 methylation was implicated in the constitutive activation of STAT3. The biallelic SHP1 gene methylation led to downregulation of SHP1 and constitutive phosphorylation of STAT3. SHP1 re-expression consequent to demethylation resulted in down-regulation of the activated phosphorylated STAT3 protein. As IL-6 is a major growth factor for myeloma cells, and IL-6 signaling acts through the Jak/STAT pathway, our results strongly suggest that SHP1 methylation might be an important epigenetic mechanism that collaborate with IL-6 in promoting the growth of the neoplastic plasma cells. However, a recent study showed that increased nuclear expression of phosphorylated STAT3, found in about 48% of myeloma patients, might not be related to the abundance of anti-apoptotic proteins including bcl-X L and Mcl-1. 39 Furthermore, the expression of cyclin D1 and phosphorylated STAT3 appeared to be mutually exclusive.
Therefore, mechanisms additional to constitutive activation of STAT3 might be involved in
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In cancer, one hit of the cell cycle control pathway may be sufficient to result in dysregulation of cellular proliferation. For instance, selective, but not concurrent, inactivation of either p16, RB or cyclin D1 has been reported in glioblastoma 40 and melanoma 41 .
Moreover, reciprocal inactivation of either RB or p16 has been reported in small and nonsmall cell lung cancers. 42, 43 Similarly, our finding of frequent epigenetic inactivation of SHP1 but not SOCS1, both being negative regulators of the Jak/STAT pathway, in myeloma also lent support to this notion.
Previous studies in myeloma have demonstrated frequent epigenetic inactivation of the INK4/CDK/RB pathway by hypermethylation of p15 and p16. Others showed frequent hypermethylation of DAP kinase in the p14/MDM2/p53 pathway. In this study, we showed frequent epigenetic inactivation of SHP1, which potentially resulted in constitutive activation of the IL-6/Jak/STAT pathway. It must be noted, however, that SHP1 methylation and STAT activation has only been demonstrated in vitro. Therefore, the functional relationship between SHP1 methylation and constitutive STAT activation in primary myeloma samples remains speculative and must be further evaluated. However, our findings together with results from previous studies suggest that gene hypermethylation might be a frequent genetic aberration in myeloma, and may collaborate with translocation and other molecular aberrations in pathogenesis. 1 Therefore, demethylating agents and histone deacetylase inhibitors are potentially useful in the treatment of myeloma.
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